Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Fischer Medical Ventures Ltd.
Source DateBoard Meeting DateDetails
23-Oct-2025 28-Oct-2025 Quarterly Results
05-Aug-2025 14-Aug-2025 A.G.M. & Quarterly Results
23-Jul-2025 28-Jul-2025 Stock Split
22-May-2025 28-May-2025 Final Dividend & Audited Results
24-Mar-2025 26-Mar-2025 Inter alia, to consider the following:- 1. Noting the Resignation of Ms. Jeena Dineshchandra Suthar (DIN: 09852258) as Independent Director of the Company with effect from closing hours of 26 th March 2025. 2. Consider and Approve on the recommendation of Nomination and Remuneration Committee the Appointment of Ms. Jaya Ankur Singhania (DIN: 01990322) as Independent Director of the Company with effect from 26 th March 2025. 3. Consider and Approve the Notice of Postal Ballot with explanatory statements and other related matters. 4. Other General Business and ancillary matters.
07-Feb-2025 14-Feb-2025 Quarterly Results
30-Dec-2024 03-Jan-2025 Inter alia, to consider and approve:- 1. The withdrawal of the proposed preferential issue which was announced by the Company on December 26, 2024; 2. The proposal for fund raising by way of preferential issue / private placement of securities for cash / other than cash, including determination of Issue Price subject to such regulatory/statutory approvals as may be required, including the approval of shareholders of the Company.; 3. The day, date, time and venue for Extra-Ordinary General Meeting of the Company; 4. The notice for Extra-Ordinary General Meeting (EOGM) of the Company; 5. To fix the date for book closure (Register of Member); 6. To appoint Mr. Nuren Lodaya Practicing Company Secretary (Membership No. 60128), proprietor of M/s. Nuren Lodaya & Associates. as Scrutinizer for conducting e-voting and poll process for General Meeting of the Company; 7. To transact other incidental and ancillary matters as may be decided by the Board with the permission of Chairperson.
05-Nov-2024 13-Nov-2024 Quarterly Results
09-Aug-2024 14-Aug-2024 Preferential Issue of shares & Quarterly Results
22-May-2024 30-May-2024 Audited Results
30-Apr-2024 04-May-2024 Inter alia, to consider and approve:- 1. The Change in management of the Company subsequent to completion of open offer in accordance with the provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; 2. The setting up of corporate office Address of the Company in Chennai, Tamil Nadu; and 3. To transact other incidental and ancillary matters as may be decided by the board
05-Feb-2024 12-Feb-2024 Quarterly Results
12-Dec-2023 15-Dec-2023 Inter alia, to consider and approve: 1. The proposal for fund raising by way of preferential issue / private placement of securities for cash / other than cash, including determination of Issue Price subject to such regulatory/statutory approvals as may be required, including the approval of shareholders of the Company.; 2. To transact other incidental and ancillary matters as may be decided by the board.
25-Oct-2023 01-Nov-2023 Quarterly Results
02-Aug-2023 12-Aug-2023 Quarterly Results
23-May-2023 29-May-2023 Quarterly Results
28-Mar-2023 30-Mar-2023 Preferential Issue of shares
06-Feb-2023 14-Feb-2023 Quarterly Results
31-Jan-2023 03-Feb-2023 Inter alia, to consider and approve:- 1. The appointment of Non-Executive Independent Women Director, subject to necessary approval of shareholders. 2. The appointment of Non-Executive Independent Director, subject to necessary approval of shareholders. 3. The appointment of Executive Director subject to necessary approval of shareholders. 4. The appointment of Chief Financial Officer, Key Managerial Personnel. 5. Approve the appointment of Internal Auditor of the Company. 6. Approve the request for reclassification in accordance with Regulation 31A of the SEBI LODR Regulations received from Shri. Sankaranarayanan G M subject to approval of the shareholders and the Stock Exchanges. 7. Any other business with the permission of chairperson
11-Nov-2022 17-Nov-2022 Quarterly Results
Page 1 of 5
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.